Back to funds
View filing
GILEAD SCIENCES, INC.
institutionalUpdated 38 days agoManaged by Gilead Sciences, Inc. • Latest filing Q2 2026
Portfolio value
$1.6B
Q2 2026
Filings
7
Quarterly 13F history
Top-10 concentration
100.0%
Weight of largest holdings
Annualized return
4.2%
Implied from 13F holdings
Portfolio value history
13F-disclosed portfolio value over 7 quarters
Show data table
| Period | Portfolio value |
|---|---|
| Q4 2024 | $1.6B |
| Q1 2025 | $1.2B |
| Q2 2025 | $1.3B |
| Q3 2025 | $1.8B |
| Q4 2025 | $1.9B |
| Q1 2026 | $2.1B |
| Q2 2026 | $1.6B |
Top holdings
5 positions as of Q2 2026
| # | Stock | Value | Shares | % Portfolio | Change |
|---|---|---|---|---|---|
| 1 | ? N/A Arcus Biosciences Inc. | $968.8M | 31.42M | 58.76% | Unchanged |
| 2 | G GLPGF Lakefront Biotherapeutics | $500.2M | 16.71M | 30.34% | Unchanged |
| 3 | ? N/A Assembly Biosciences Inc. | $136.8M | 4.98M | 8.30% | Added(+10.5%) |
| 4 | ? N/A Kyverna Therapeutics Inc. | $36.8M | 4.13M | 2.23% | Unchanged |
| 5 | ? N/A Xilio Therapeutics Inc. | $6.2M | 650.4K | 0.38% | Unchanged |